JPI-547 disrupts the Wnt/β-catenin pathway in RNF43-mutated cells and inhibits the oncogenic YAP pathway, highlighting its multifaceted therapeutic potential in PDAC with HRD or Wnt-addiction. This evidence concerns the gene YAP1 and hypoparathyroidism-retardation-dysmorphism syndrome.